Gilead Sciences (GILD) has decided to price remdesivir at $390 per vial for governments of developed countries. The company said this price will be offered to all governments in developed countries around the world where remdesivir is approved or authorized for use. In the U.S. also, the same government price of $390 per vial will apply. Based on current treatment patterns, the vast majority of patients are anticipated to receive a 5-day treatment course using 6 vials of remdesivir, which equates to $2,340 per patient. For U.S. private insurance companies, the price will be $520 per vial.
from RTT - Biotech https://ift.tt/3dFAUQN
via IFTTT
No comments:
Post a Comment